Browsing by Author "STORDAL, BRITTA KRISTINA"
Now showing items 1-17 of 17
-
A 39kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome.
STORDAL, BRITTA KRISTINA (John Wiley, 2008)Transfected human ASK1 produces a 150kDa protein. However, we have detected endogenous ASK1 predominantly as 39kDa and 50kDa C-terminal and 75kDa and 110kDa N-terminal fragments in a panel of non-transfected cancer cell ... -
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
STORDAL, BRITTA KRISTINA (2013)Mutations in BRCA1/2 increase the risk of developing breast and ovarian cancer. Germline BRCA1/2 mutations occur in 8.6-13.7% of unselected epithelial ovarian cancers, somatic mutations are also frequent. BRCA1/2 mutated ... -
BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
STORDAL, BRITTA KRISTINA (2012)Introduction: Germline mutations in DNA repair genes BRCA1/2 increase the risk of developing breast and ovarian cancer. Germline BRCA1/2 mutations occur in 8.6-13.7% of unselected epithelial ovarian cancers, somatic mutations ... -
A cloud computing database for data extraction in a Cochrane review
STORDAL, BRITTA KRISTINA (2013)Background: An online database was needed for the Cochrane review ?Taxanes for the treatment of platinum pre-treated epithelial ovarian cancer? for several reasons. Firstly, a large amount of clinical parameters were to ... -
Collateral Sensitivity to Cisplatin in KB-8-5-11 Drug-resistant Cancer Cells.
STORDAL, BRITTA KRISTINA (2014) -
THE EMT-ACTIVATOR ZEB1 IS UNRELATED TO PLATINUM DRUG RESISTANCE IN OVARIAN CANCER BUT PREDICTIVE OF SURVIVAL
STORDAL, BRITTA KRISTINA (2014)Background: Ovarian cancer is treated by surgery followed by platinum/taxane combination chemotherapy. Initial response rates are high, but up to 80% of ovarian cancer patients will eventually relapse with drug-resistant ... -
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
STORDAL, BRITTA KRISTINA (Springer Verlag, 2009)Background: The H69CIS200 and H69OX400 cell lines are novel models of low- level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather ... -
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
STORDAL, BRITTA KRISTINA (2011)Background: Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops. Targeted therapies, such as tyrosine ... -
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review.
STORDAL, BRITTA KRISTINA (WB Saunders, 2007)Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of ... -
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
STORDAL, BRITTA KRISTINA (Springer, 2006)Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant ... -
Resistance relationships between platinum and parp-inhibitors in ovarian cancer.
STORDAL, BRITTA KRISTINA (2012) -
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
STORDAL, BRITTA KRISTINA (2012)The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan ... -
Similar chromosomal changes in cisplatin-resistant and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
STORDAL, BRITTA KRISTINA (2006)Small cell lung cancer (SCLC) initially responds well to DNA damaging drugs such as cisplatin, however this is transitory as resistance normally develops. To investigate whether changes in chromosomal copy number caused ... -
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1.
STORDAL, BRITTA KRISTINA (Bentham Science, 2009)A systematic review of cell models of acquired drug resistance not involving genetic manipulation showed that 80% of cell models had an inverse resistance relationship between cisplatin and paclitaxel[1]. Here we ... -
A systematic review of platinum and taxane resitance from bench to clinic: An inverse relationship.
STORDAL, BRITTA KRISTINA (WB Saunders, 2007)We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance. Medline was searched for 1) cell models of acquired drug ... -
Understanding cisplatin resistance using cellular models.
STORDAL, BRITTA KRISTINA (John Wiley, 2007)Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of ...